Local induction of bladder Th1 responses to combat urinary tract infections
- aDepartment of Immunology, Duke University Medical Center, Durham, NC 27710;
- bDepartment of Pathology, Duke University Medical Center, Durham, NC 27710;
- cDepartment of Biomedical Research, National Jewish Health, Denver, CO 80206;
- dDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045;
- eDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, NC 27710;
- fProgram in Emerging Infectious Diseases, Duke–National University of Singapore, 169857 Singapore
See allHide authors and affiliations
Edited by Rino Rappuoli, GlaxoSmithKline, Siena, Italy, and approved January 22, 2021 (received for review January 5, 2021)

Significance
Urinary tract infections (UTIs) are the second most common bacterial infections. Caring for UTI patients is very difficult and often perplexing. We typically view our immune system as an adaptive line of defense that becomes more responsive to specific pathogens after episodes of infection. However, the opposite is seen in these patients, in whom each infection actually increases the risk of a subsequent infection. Our group recently identified the underlying basis as a highly Th2-biased response in bladder that inhibits Th1-mediated bacterial clearance. To resolve this situation, we investigated whether immunizing mice intravesically with bacterial antigens combined with a Th1-skewing adjuvant (CpG) would evoke a more balanced and protective immune response.
Abstract
Given the high frequency of urinary tract infections (UTIs) and their recurrence, there is keen interest in developing effective UTI vaccines. Currently, most vaccine studies, including those in humans, involve parenteral vaccination aimed at evoking and sustaining elevated levels of systemic antibody directed at the uropathogens. In view of recent reports of aberrant Th2-biased bladder immune responses to infection, we hypothesized that immunizing mice intravesically with antigens from uropathogenic Escherichia coli (UPEC) combined with a Th1-skewing adjuvant could correct this defect and promote protection against UTIs. Here we report that compared with mice immunized subcutaneously with this vaccine combination, intravesically immunized mice were markedly more protected from UTIs because of their distinctive ability to recruit Th1 cells into the bladder. This mode of vaccination was effective even in mice that experienced multiple UTIs and displayed pronounced aberrant bladder immune responses. Thus, intravesical vaccination with one or more UPEC antigens to induce bladder Th1 responses represents a superior strategy to combat UTIs, especially in UTI-prone subjects.
Footnotes
- ↵1To whom correspondence may be addressed. Email: soman.abraham{at}duke.edu.
Author contributions: J.W., R.L.R., and S.N.A. designed research; J.W. and C.B. performed research; R.L.R. contributed new reagents/analytic tools; J.W. and S.N.A. analyzed data; and J.W., C.B., R.L.R., and S.N.A. wrote the paper.
The authors declare no competing interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2026461118/-/DCSupplemental.
Data Availability
All study data are included in the main text and SI Appendix.
Published under the PNAS license.
References
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- J. Wu et al
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- M. A. Mulvey,
- J. D. Schilling,
- S. J. Hultgren
- ↵
- J. Wu,
- Y. Miao,
- S. N. Abraham
- ↵
- K. E. Sivick,
- H. L. Mobley
- ↵
- ↵
- R. D. Klein,
- S. J. Hultgren
- ↵
- ↵
- ↵
- ↵
- ↵
- L. A. Mike,
- S. N. Smith,
- C. A. Sumner,
- K. A. Eaton,
- H. L. Mobley
- ↵
- V. S. Forsyth et al
- ↵
- ↵
- Z. Li,
- K. E. Wang,
- X. L. Zhou,
- J. Zhou,
- C. H. Ye
- ↵
- ↵
- ↵
- ↵
- ↵
- ↵
- R. L. Reinhardt et al
- ↵
- S. Normark et al
- ↵
- ↵
- ↵
- ↵
- ↵
- D. Sen,
- L. Forrest,
- T. B. Kepler,
- I. Parker,
- M. D. Cahalan
- ↵
- J. Zhu,
- W. E. Paul
- ↵
- P. E. Fields,
- S. T. Kim,
- R. A. Flavell
- ↵
- H. Bashyam
- ↵
- J. R. Lukens,
- P. K. Anand
- ↵
- ↵
- M. R. Karam,
- M. Oloomi,
- M. Mahdavi,
- M. Habibi,
- S. Bouzari
- ↵
- ↵
- C. A. Sarkissian,
- C. J. Alteri,
- H. L. T. Mobley
- ↵
- ↵
- ↵
- ↵
- ↵
- T. Antunes-Lopes et al
- ↵
- ↵
- C. Biot et al
- ↵
- L. Derré et al
- ↵
- M. Kates et al
- ↵
- ↵
- S. Domingos-Pereira et al
- ↵
- World Health Organization
- ↵
- L. Mocé-Llivina,
- M. Muniesa,
- H. Pimenta-Vale,
- F. Lucena,
- J. Jofre
Log in using your username and password
Log in through your institution
Purchase access
Subscribers, for more details, please visit our Subscriptions FAQ.
Please click here to log into the PNAS submission website.
Citation Manager Formats
Article Classifications
- Biological Sciences
- Immunology and Inflammation